CN1890219A - 用作葡糖激酶(glk)激活剂的苯甲酰基氨基吡啶基羧酸衍生物 - Google Patents

用作葡糖激酶(glk)激活剂的苯甲酰基氨基吡啶基羧酸衍生物 Download PDF

Info

Publication number
CN1890219A
CN1890219A CNA2004800362365A CN200480036236A CN1890219A CN 1890219 A CN1890219 A CN 1890219A CN A2004800362365 A CNA2004800362365 A CN A2004800362365A CN 200480036236 A CN200480036236 A CN 200480036236A CN 1890219 A CN1890219 A CN 1890219A
Authority
CN
China
Prior art keywords
compound
formula
salt
prodrug
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800362365A
Other languages
English (en)
Chinese (zh)
Inventor
P·W·R·考尔克特
C·约翰斯通
D·麦克雷彻尔
K·G·派克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1890219A publication Critical patent/CN1890219A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA2004800362365A 2003-12-05 2004-12-02 用作葡糖激酶(glk)激活剂的苯甲酰基氨基吡啶基羧酸衍生物 Pending CN1890219A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0328178.9A GB0328178D0 (en) 2003-12-05 2003-12-05 Compounds
GB0328178.9 2003-12-05

Publications (1)

Publication Number Publication Date
CN1890219A true CN1890219A (zh) 2007-01-03

Family

ID=29764609

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800362365A Pending CN1890219A (zh) 2003-12-05 2004-12-02 用作葡糖激酶(glk)激活剂的苯甲酰基氨基吡啶基羧酸衍生物

Country Status (6)

Country Link
US (1) US20090062351A1 (enExample)
EP (1) EP1697325A1 (enExample)
JP (1) JP2007519618A (enExample)
CN (1) CN1890219A (enExample)
GB (1) GB0328178D0 (enExample)
WO (1) WO2005056530A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105451A (zh) * 2008-05-16 2011-06-22 塔克达圣地亚哥公司 葡糖激酶活化剂

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
EP1718624B1 (en) * 2004-02-18 2009-03-25 AstraZeneca AB Benzamide derivatives and their use as glucokinase activating agents
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
NZ564608A (en) 2005-07-09 2009-09-25 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
CN101437512A (zh) * 2006-01-27 2009-05-20 阿雷生物药品公司 葡萄糖激酶活化剂
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
SA07280576B1 (ar) * 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
JP5572549B2 (ja) 2007-08-13 2014-08-13 リガンド・ファーマシューティカルズ・インコーポレイテッド グルコキナーゼの新規な活性化剤
JP2011529955A (ja) 2008-08-04 2011-12-15 アストラゼネカ アクチボラグ 治療薬414
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
WO2020037109A1 (en) * 2018-08-17 2020-02-20 Dow Agrosciences Llc Processes for fluorination

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1561350A (en) * 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
US5466715A (en) * 1991-12-31 1995-11-14 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
US5258407A (en) * 1991-12-31 1993-11-02 Sterling Winthrop Inc. 3,4-disubstituted phenols-immunomodulating agents
AUPO395396A0 (en) * 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
US6200995B1 (en) * 1998-01-29 2001-03-13 Tularik Inc. PPAR-γ modulators
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102299D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0226931D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105451A (zh) * 2008-05-16 2011-06-22 塔克达圣地亚哥公司 葡糖激酶活化剂
CN102105451B (zh) * 2008-05-16 2013-11-13 塔克达加利福尼亚股份有限公司 葡糖激酶活化剂

Also Published As

Publication number Publication date
JP2007519618A (ja) 2007-07-19
EP1697325A1 (en) 2006-09-06
GB0328178D0 (en) 2004-01-07
WO2005056530A1 (en) 2005-06-23
US20090062351A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
CN1890219A (zh) 用作葡糖激酶(glk)激活剂的苯甲酰基氨基吡啶基羧酸衍生物
CN1898209A (zh) 葡糖激酶调节剂吡啶羧酸衍生物
CN1886401A (zh) 用作葡糖激酶激活剂的苯甲酰基氨基吡啶基羧酸衍生物
CN1886377A (zh) 用作葡糖激酶(glk)激活剂的苯甲酰基氨基吡啶基羧酸衍生物
CN1294135C (zh) 作为蛋白激酶抑制剂的吡咯并嘧啶
CN101039915A (zh) 用于治疗ⅱ型糖尿病和肥胖症的苯氧基苯甲酰胺化合物
CN1219768C (zh) 作为mek酶的抑制剂的喹啉衍生物
CN100343258C (zh) 新的4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物
CN1255403C (zh) 用作磷酸二酯酶抑制剂的β-咔啉衍生物
CN1186324C (zh) 稠合杂芳基衍生物
CN1247586C (zh) 治疗神经退化性疾病的取代的2-嘧啶基-6,7,8,9-四氢嘧啶并[1,2-a]嘧啶-4-酮及7-嘧啶基-2,3-二氢咪唑并[1,2-a]嘧啶-5(1h)酮衍生物
CN1568185A (zh) 影响葡糖激酶的化合物
CN1221544C (zh) 吡唑环腺苷酸-特异性磷酸二酯酶抑制剂
CN1703405A (zh) 用作糖原合酶激酶3β抑制剂的氨基苯甲酰胺衍生物
CN1520296A (zh) 作为葡糖激酶(glk)调制剂的氨基烟酸盐衍生物
CN1816549A (zh) 磷脂酰肌醇3-激酶抑制剂
CN1440401A (zh) 治疗由npy5受体介导的疾病的氨基取代的二苯并噻吩衍生物
CN101031304A (zh) Hcv抑制性双环嘧啶
CN1494541A (zh) Erk2的杂环抑制剂及其应用
CN1882591A (zh) 具有PDE-5抑制活性的5,7-二氨基吡唑并[4,3-d]嘧啶
CN1524081A (zh) 抑制细胞增殖的嘧啶衍生物
CN1056879A (zh) 吡咯衍生物及其制备方法
CN101031569A (zh) 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
CN1671696A (zh) 激酶抑制剂
CN1439009A (zh) 咪唑并嘧啶衍生物和三唑并嘧啶衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication